GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » 5-Year Yield-on-Cost %

Cidara Therapeutics (Cidara Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics 5-Year Yield-on-Cost %?

Cidara Therapeutics's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for Cidara Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



CDTX's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.92
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Cidara Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Cidara Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cidara Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's 5-Year Yield-on-Cost % falls into.



Cidara Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Cidara Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Cidara Therapeutics  (NAS:CDTX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Cidara Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cidara Therapeutics (Cidara Therapeutics) Business Description

Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Executives
Leslie Tari officer: Chief Scientific Officer C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Taylor Sandison officer: Chief Medical Officer 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein director, officer: President & CEO 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Shane Ward officer: CHIEF LEGAL OFFICER C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Preetam Shah officer: CFO & CBO C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala officer: Chief Medical Officer 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson officer: Dir. of Finance & Controller 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston director C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder director 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher director 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121

Cidara Therapeutics (Cidara Therapeutics) Headlines

From GuruFocus